Publications | Lund University Publications

11 – 15 of 15

show: 10
|
sort: year (new to old)

News feed Embed this list Save this search Mark all Export

Cancel

Embed this list

copy and paste the html snippet below into your own page:

<iframe src="https://lup.lub.lu.se/search/publication?embed=1&q=keywords+exact+%22Docetaxel%22&amp;hide_pagination=1&amp;hide_info=1&amp;hide_options=1"
  width="100%"
  height="400"
  allowtransparency="true"
  frameborder="0">
</iframe>

« previous
1
2
next »

2007
Mark Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer
Albertsson, M. ; Johansson, B. ; Friesland, S. ; Kadar, Lianna ^LU ; Letocha, H. ; Frykholm, G. and Wagenius, G. (2007) In Medical Oncology 24(4). p.407-412
- Contribution to journal › Article
2003
Mark Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer
Luoma, ML ; Hakamies-Blomqvist, L ; Sjostrom, J ; Pluzanska, A ; Ottoson, S ; Mouridsen, H ; Bengtsson, NO ; Bergh, J ; Malmström, Per ^LU and Valvere, V , et al. (2003) In European Journal of Cancer 39(10). p.1370-1376
- Contribution to journal › Article
2002
Mark C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer
Sjostrom, J ; Collan, J ; von Boguslawski, K ; Franssila, K ; Bengtsson, NO ; Mjaaland, I ; Malmström, Per ^LU ; Ostenstad, B ; Wist, E and Valvere, V , et al. (2002) In European Journal of Cancer 38(4). p.535-542
- Contribution to journal › Article
2000
Mark Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer
Sjöström, J ; Blomqvist, C ; Heikkilä, P ; Boguslawski, K V ; Räisänen-Sokolowski, A ; Bengtsson, N O ; Mjaaland, I ; Malmström, Per ^LU ; Ostenstadt, B and Bergh, J , et al. (2000) In Clinical Cancer Research 6(8). p.3103-3110
- Contribution to journal › Article
Mark Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group
Hakamies-Blomqvist, L ; Luoma, M ; Sjöström, J ; Pluzanska, A ; Sjödin, M ; Mouridsen, H ; Ostenstad, B ; Mjaaland, I ; Ottosson-Lönn, S and Bergh, J , et al. (2000) In European Journal of Cancer 36(11). p.7-1411
- Contribution to journal › Article

« previous
1
2
next »

your query:: Remove keywords: Docetaxel